PTC Therapeutics (PTCT) Stock: Charts & Financials

PTC Therapeutics, Inc.(PTCT)

Biotechnology · Warren, NJ

$63.70+0.05 (+0.08%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About PTC Therapeutics, Inc.

PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications. Among its commercialized products, PTC Therapeutics provides Translarna and Emflaza, offering therapeutic options for Duchenne muscular dystrophy patients in the European Economic Area and the United States. Translarna also addresses nonsense mutation Duchenne muscular dystrophy in Brazil and Russia. The company additionally commercializes Tegsedi and Waylivra for various rare conditions throughout Latin America and the Caribbean. Furthermore, in Brazil, PTC Therapeutics distributes Evrysdi as a treatment for spinal muscular atrophy (SMA) in patients aged two months and older. Leveraging its proprietary splicing platform, the company is also actively developing PTC518, a promising therapeutic candidate aimed at treating Huntington's disease. To bolster its research and development capabilities, PTC Therapeutics has established strategic collaborations, including partnerships with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation, focusing on advancing drug discovery and development research, particularly in regenerative medicine. Additionally, it collaborates with Akcea Therapeutics, Inc. for the commercialization of Tegsedi and Waylivra in the Latin America and Caribbean region. Established in 1998, PTC Therapeutics, Inc. maintains its corporate headquarters in South Plainfield, New Jersey.

Warren, NJ

991 employees

www.ptcbio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Matthew Klein

View full financials

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	1.01B	360.52M	272.55M	164.68M	211.01M	178.88M	1.18B	213.17M	196.79M
Cost of Goods Sold	180.19M	19.92M	28.03M	16.30M	115.94M	11.42M	12.86M	16.28M	10.85M
Gross Profit	828.57M	340.60M	244.52M	148.38M	95.07M	167.46M	1.16B	196.89M	185.94M
Gross Profit Margin	82.1%	94.5%	89.7%	90.1%	45.1%	93.6%	98.9%	92.4%	94.5%
Total Operating Expenses	712.31M	191.62M	198.64M	230.00M	92.05M	202.41M	193.01M	359.28M	240.45M
Research & Development	433.31M	99.15M	100.87M	133.13M	100.16M	112.99M	108.97M	124.77M	161.41M
Selling, General & Administrative	351.33M	80.63M	86.18M	100.47M	84.05M	85.26M	80.96M	84.68M	73.46M
Operating Income (EBIT)	116.25M	148.98M	45.89M	-81.62M	3.02M	-34.96M	970.23M	-162.39M	-54.51M
Operating Margin	11.5%	41.3%	16.8%	-49.6%	1.4%	-19.5%	82.5%	-76.2%	-27.7%
Income Before Tax (EBT)	-67.07M	97.55M	-2.46M	-139.08M	-23.07M	-71.05M	929.83M	-94.70M	-97.99M
Interest Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	185.29M	48.48M	49.03M	55.19M	32.59M	30.36M	34.09M	41.06M	41.61M
Other Income/Expense	-183.33M	-51.43M	-48.35M	-57.46M	-26.09M	-36.09M	-40.40M	67.69M	-43.48M
Net Income	-38.38M	83.50M	-2.81M	-134.97M	15.90M	-64.85M	866.56M	-65.89M	-106.65M
Income Tax Expense	-28.69M	14.05M	347K	-4.12M	-38.97M	-6.20M	63.27M	-28.81M	8.66M
Net Profit Margin	-3.8%	23.2%	-1.0%	-82.0%	7.5%	-36.3%	73.7%	-30.9%	-54.2%
EBITDA	171.55M	164.85M	61.30M	-68.72M	14.13M	-27.37M	977.45M	-155.63M	-48.02M
EBITDA Margin	17.0%	45.7%	22.5%	-41.7%	6.7%	-15.3%	83.1%	-73.0%	-24.4%
Depreciation & Amortization	55.30M	15.87M	15.41M	12.90M	11.11M	7.58M	7.22M	6.76M	6.49M
EPS Basic	-0.49	1.01	-0.03	-1.67	0.20	-0.83	11.09	-0.85	-1.39
EPS Diluted	-0.58	0.92	-0.03	-1.67	0.20	-0.83	10.04	-0.85	-1.39
Weighted Average Basic Shares	83.01M	83.01M	82.52M	80.69M	81.50M	78.15M	78.12M	77.20M	76.93M
Weighted Average Diluted Shares	92.02M	92.02M	82.52M	80.69M	87.12M	78.15M	86.39M	77.20M	76.93M

Quarterly Report

TTM

Quarter ended Jun 2026

Quarter ended Mar 2026

Quarter ended Dec 2025

Quarter ended Sep 2025

Quarter ended Jun 2025

Quarter ended Mar 2025

Quarter ended Dec 2024

Quarter ended Sep 2024

Revenue

1.01B

360.52M

272.55M

164.68M

211.01M

178.88M

1.18B

213.17M

196.79M

Cost of Goods Sold

180.19M

19.92M

28.03M

16.30M

115.94M

11.42M

12.86M

16.28M

10.85M

Gross Profit

828.57M

340.60M

244.52M

148.38M

95.07M

167.46M

1.16B

196.89M

185.94M

Gross Profit Margin

82.1%

94.5%

89.7%

90.1%

45.1%

93.6%

98.9%

92.4%

94.5%

Total Operating Expenses

712.31M

191.62M

198.64M

230.00M

92.05M

202.41M

193.01M

359.28M

240.45M

Research & Development

433.31M

99.15M

100.87M

133.13M

100.16M

112.99M

108.97M

124.77M

161.41M

Selling, General & Administrative

351.33M

80.63M

86.18M

100.47M

84.05M

85.26M

80.96M

84.68M

73.46M

Operating Income (EBIT)

116.25M

148.98M

45.89M

-81.62M

3.02M

-34.96M

970.23M

-162.39M

-54.51M

Operating Margin

11.5%

41.3%

16.8%

-49.6%

1.4%

-19.5%

82.5%

-76.2%

-27.7%

Income Before Tax (EBT)

-67.07M

97.55M

-2.46M

-139.08M

-23.07M

-71.05M

929.83M

-94.70M

-97.99M

Interest Income

N/A

Interest Expense

185.29M

48.48M

49.03M

55.19M

32.59M

30.36M

34.09M

41.06M

41.61M

Other Income/Expense

-183.33M

-51.43M

-48.35M

-57.46M

-26.09M

-36.09M

-40.40M

67.69M

-43.48M

Net Income

-38.38M

83.50M

-2.81M

-134.97M

15.90M

-64.85M

866.56M

-65.89M

-106.65M

Income Tax Expense

-28.69M

14.05M

347K

-4.12M

-38.97M

-6.20M

63.27M

-28.81M

8.66M

Net Profit Margin

-3.8%

23.2%

-1.0%

-82.0%

7.5%

-36.3%

73.7%

-30.9%

-54.2%

EBITDA

171.55M

164.85M

61.30M

-68.72M

14.13M

-27.37M

977.45M

-155.63M

-48.02M

EBITDA Margin

17.0%

45.7%

22.5%

-41.7%

6.7%

-15.3%

83.1%

-73.0%

-24.4%

Depreciation & Amortization

55.30M

15.87M

15.41M

12.90M

11.11M

7.58M

7.22M

6.76M

6.49M

EPS Basic

-0.49

1.01

-0.03

-1.67

0.20

-0.83

11.09

-0.85

-1.39

EPS Diluted

-0.58

0.92

-0.03

-1.67

0.20

-0.83

10.04

-0.85

-1.39

Weighted Average Basic Shares

83.01M

82.52M

80.69M

81.50M

78.15M

78.12M

77.20M

76.93M

Weighted Average Diluted Shares

92.02M

82.52M

80.69M

87.12M

78.15M

86.39M

77.20M

76.93M

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	1.73B	806.78M	937.82M	698.80M	538.59M	380.77M	306.98M	264.73M
Cost of Goods Sold	71.75M	57.40M	65.49M	44.68M	32.33M	18.94M	12.13M	12.67M
Gross Profit	1.66B	749.38M	872.34M	654.12M	506.26M	361.82M	294.85M	252.06M
Gross Profit Margin	95.9%	92.9%	93.0%	93.6%	94.0%	95.0%	96.0%	95.2%
Total Operating Expenses	802.39M	1.05B	1.31B	1.10B	880.71M	793.59M	536.00M	348.41M
Research & Development	455.25M	534.48M	666.56M	651.50M	540.68M	477.64M	257.45M	171.98M
Selling, General & Administrative	347.14M	300.91M	332.54M	326.00M	285.77M	245.16M	202.54M	153.55M
Operating Income (EBIT)	856.51M	-302.57M	-439.50M	-447.41M	-374.44M	-431.77M	-241.16M	-115.69M
Operating Margin	49.5%	-37.5%	-46.9%	-64.0%	-69.5%	-113.4%	-78.6%	-43.7%
Income Before Tax (EBT)	696.62M	-363.12M	-696.11M	-587.49M	-518.34M	-402.93M	-239.93M	-128.11M
Interest Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	152.23M	166.99M	129.18M	90.87M	86.02M	56.35M	12.49M	12.55M
Other Income/Expense	-159.89M	-60.55M	-256.61M	-140.08M	-143.90M	28.84M	1.23M	-12.43M
Net Income	682.64M	-363.30M	-626.60M	-559.02M	-523.90M	-438.16M	-251.58M	-128.08M
Income Tax Expense	13.97M	176K	-69.51M	-28.47M	5.56M	35.23M	11.65M	-29K
Net Profit Margin	39.4%	-45.0%	-66.8%	-80.0%	-97.3%	-115.1%	-82.0%	-48.4%
EBITDA	895.32M	-226.91M	-202.91M	-318.57M	-310.31M	-388.28M	-208.98M	-89.60M
EBITDA Margin	51.7%	-28.1%	-21.6%	-45.6%	-57.6%	-102.0%	-68.1%	-33.8%
Depreciation & Amortization	38.81M	75.66M	236.59M	128.84M	64.13M	43.49M	32.18M	26.09M
EPS Basic	8.58	-4.73	-8.37	-7.79	-7.43	-6.64	-4.27	-2.75
EPS Diluted	7.78	-4.73	-8.37	-7.79	-7.43	-6.64	-4.27	-2.75
Weighted Average Basic Shares	79.53M	76.85M	74.84M	71.73M	70.47M	66.03M	58.86M	46.58M
Weighted Average Diluted Shares	88.31M	76.85M	74.84M	71.73M	70.47M	66.03M	58.86M	46.58M

Annual Report

12/31/2025

12/31/2024

12/31/2023

12/31/2022

12/31/2021

12/31/2020

12/31/2019

12/31/2018

Revenue

1.73B

806.78M

937.82M

698.80M

538.59M

380.77M

306.98M

264.73M

Cost of Goods Sold

71.75M

57.40M

65.49M

44.68M

32.33M

18.94M

12.13M

12.67M

Gross Profit

1.66B

749.38M

872.34M

654.12M

506.26M

361.82M

294.85M

252.06M

Gross Profit Margin

95.9%

92.9%

93.0%

93.6%

94.0%

95.0%

96.0%

95.2%

Total Operating Expenses

802.39M

1.05B

1.31B

1.10B

880.71M

793.59M

536.00M

348.41M

Research & Development

455.25M

534.48M

666.56M

651.50M

540.68M

477.64M

257.45M

171.98M

Selling, General & Administrative

347.14M

300.91M

332.54M

326.00M

285.77M

245.16M

202.54M

153.55M

Operating Income (EBIT)

856.51M

-302.57M

-439.50M

-447.41M

-374.44M

-431.77M

-241.16M

-115.69M

Operating Margin

49.5%

-37.5%

-46.9%

-64.0%

-69.5%

-113.4%

-78.6%

-43.7%

Income Before Tax (EBT)

696.62M

-363.12M

-696.11M

-587.49M

-518.34M

-402.93M

-239.93M

-128.11M

Interest Income

N/A

Interest Expense

152.23M

166.99M

129.18M

90.87M

86.02M

56.35M

12.49M

12.55M

Other Income/Expense

-159.89M

-60.55M

-256.61M

-140.08M

-143.90M

28.84M

1.23M

-12.43M

Net Income

682.64M

-363.30M

-626.60M

-559.02M

-523.90M

-438.16M

-251.58M

-128.08M

Income Tax Expense

13.97M

176K

-69.51M

-28.47M

5.56M

35.23M

11.65M

-29K

Net Profit Margin

39.4%

-45.0%

-66.8%

-80.0%

-97.3%

-115.1%

-82.0%

-48.4%

EBITDA

895.32M

-226.91M

-202.91M

-318.57M

-310.31M

-388.28M

-208.98M

-89.60M

EBITDA Margin

51.7%

-28.1%

-21.6%

-45.6%

-57.6%

-102.0%

-68.1%

-33.8%

Depreciation & Amortization

38.81M

75.66M

236.59M

128.84M

64.13M

43.49M

32.18M

26.09M

EPS Basic

8.58

-4.73

-8.37

-7.79

-7.43

-6.64

-4.27

-2.75

EPS Diluted

7.78

-4.73

-8.37

-7.79

-7.43

-6.64

-4.27

-2.75

Weighted Average Basic Shares

79.53M

76.85M

74.84M

71.73M

70.47M

66.03M

58.86M

46.58M

Weighted Average Diluted Shares

88.31M